Abstracts tagged "inflammatory back pain and spondylarthritis"

Abstract Number: 705 • 2016 ACR/ARHP Annual Meeting
Is a Positive Family History of Spondyloarthritis of Value in Patients with Chronic Back Pain? Results from Two Large Early Back Pain Cohorts
Zineb Ez-Zaitouni¹, Laure Gossec², Inger Jorid Berg³, Robert Landewé⁴, Maikel van Oosterhout⁵, Mariagrazia Lorenzin⁶, Maxime Dougados⁷, Désirée van der Heijde⁸ and Floris van Gaalen¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Amsterdam Medical Center, Amsterdam, Netherlands, ⁵Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁶Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy, ⁷Paris-Descartes University, Paris, France, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: To assess whether presence of spondyloarthritis (SpA) manifestations in first- and second-degree relatives of patients with chronic back pain (CBP) is associated with higher…
Abstract Number: 2062 • 2015 ACR/ARHP Annual Meeting
How Reliable Is Self-Evaluation of Symptoms of Inflammatory Back Pain By Patients?
Denis Poddubnyy¹, Inge Spiller¹, Joachim Sieper¹ and Martin Rudwaleit^1,2, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: Inflammatory back pain (IBP) is regarded as an important clinical parameter of axial spondyloarthritis (axSpA) and is often used in a diagnostic approach. Usually…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].